Myriad Genetics to Present at the Bank of America Health Care Conference
May 02 2016 - 7:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that R. Bryan
Riggsbee, chief financial officer, Myriad Genetics, is scheduled to
present at the 2016 Bank of America Healthcare Conference at
3:40 p.m. PDT (6:40 pm EDT) on May 11, 2016, at the Encore at Wynn
in Las Vegas. The presentation will be available to
interested parties through a live audio webcast accessible through
a link in the investor information section of Myriad’s website at
www.myriad.com.
About Myriad GeneticsMyriad
Genetics Inc., is a leading personalized medicine company dedicated
to being a trusted advisor transforming patient lives worldwide
with pioneering molecular diagnostics. Myriad discovers and
commercializes molecular diagnostic tests that: determine the risk
of developing disease, accurately diagnose disease, assess the risk
of disease progression, and guide treatment decisions across six
major medical specialties where molecular diagnostics can
significantly improve patient care and lower healthcare
costs. Myriad is focused on three strategic
imperatives: transitioning and expanding its hereditary
cancer testing markets, diversifying its product portfolio through
the introduction of new products and increasing the revenue
contribution from international markets. For more information
on how Myriad is making a difference, please visit the Company's
website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis,
Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk
Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor
BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks
or registered trademarks of Myriad Genetics, Inc. or its wholly
owned subsidiaries in the United States and foreign countries.
MYGN-F, MYGN-G
Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024